data safety monitoring board (Merck & Co)
86
Structured Review
Merck & Co
data safety monitoring board
Data Safety Monitoring Board, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+safety+monitoring/pm41171750-34-3-11
Average 86 stars, based on 1 article reviews
Data Safety Monitoring Board, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+safety+monitoring/pm41171750-34-3-11
Average 86 stars, based on 1 article reviews
data safety monitoring board - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab. Article Snippet: Author EB has been member of Data Safety Monitoring Board or Advisory Board of Article Title: Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab Article Snippet: Author EB has been member of Data Safety Monitoring Board or Advisory Board of Activation Assay:Article Title: Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction Article Snippet: Dr Swedberg reports consulting for Novartis. .. Dr Zile reports grants and personal fees from Novartis for being a member of the PARAGON-HF Executive Steering Committee and a local investigator; personal fees from Abbott for serving on the executive committee of the GUIDE-HF (Hemodynamic-Guided Management of Heart Failure) trial; personal fees for consulting on product development from Boston Scientific; grants and personal fees for serving on the Executive Steering Committee and being a local investigator for the BeAT HF trial (Baroreflex Activation Therapy for Heart Failure Pivotal Trial) from CVRx; personal fees for serving on the eligibility committee of the SOLVE trial (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients) from EBR; personal fees for serving on the Clinical Events Committee of the SIRONA trial (A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Heart Failure System in NYHA Class III Heart Failure Patients) from Endotronics; personal fees for serving on the Executive Steering Committee of the CAPACITY HFpEF trial (A Study of the Effect of IW1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction) from Ironwood; personal fees for serving on the data safety monitoring board of the Article Title: Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF Article Snippet: Dr Desai has received consulting fees from Abbott, Biofourmis, Boston Scientific, Boehringer Ingelheim, DalCor Pharmaceuticals, and Regeneron; grant support (paid to Brigham and Women’s Hospital) and consulting fees from Alnylam Pharmaceuticals and Novartis, and advisory board fees from Corvidia and Relypsa. .. Dr Zile reports grants and personal fees from Novartis for being a member of the PARAGON‐HF Executive Steering Committee and a local investigator; personal fees from Abbott for serving on the executive committee of the GUIDE‐HF (Hemodynamic‐Guided Management of Heart Failure) trial; personal fees for consulting on product development from Boston Scientific; grants and personal fees for serving on the Executive Steering Committee and being a local investigator for the BeAT HF trial (Baroreflex Activation Therapy for Heart Failure Pivotal Trial) from CVRx; personal fees for serving on the eligibility committee of the SOLVE trial (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non‐Responders and Previously Untreatable Patients) from EBR; personal fees for serving on the Clinical Events Committee of the SIRONA trial (A Prospective, Multi‐Center, Open‐Label, Single‐Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Heart Failure System in New York Heart Association Class III Heart Failure Patients) from Endotronics; personal fees for serving on the Executive Steering Committee of the CAPACITY HFpEF trial (A Study of the Effect of IW‐1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction) from Ironwood; personal fees for serving on the data safety monitoring board of the Infection:Article Title: Utilization of interdisciplinary in-hospital early rehabilitation in COVID-19 patients - a multicenter cohort study in the National Pandemic Cohort Network (NAPKON) in Germany. Article Snippet: .. JJV participate on |